Salmeterol ticarcoson powder inhaler has no hepatic impairment for patients with normal hepatic function, for patients with liver disease, as the drug needs to be metabolized by the liver, there is a possibility of causing hepatic impairment. Salmeterol ticarcoson is a compound preparation whose components are: salmeterol and fluticasone propionate. Since both salmeterol and fluticasone propionate are mainly metabolized by the liver, hepatic impairment may lead to accumulation of salmeterol and fluticasone propionate in the plasma, therefore, patients with liver disease need to closely monitor their liver function when inhaling this drug for a long period of time. If abnormal liver function occurs during the inhalation of salmeterol ticarcoson, it is necessary to consult a doctor in time and change the appropriate inhaler under the guidance of a specialist.